Episode 68: Guardant Health

In this episode of Petri Dish Perspectives, we explore the story of Guardant Health, one of the companies leading the shift toward blood-based cancer detection and precision oncology. Founded by genomic scientists Helmy Eltoukhy and AmirAli Talasaz, Guardant is betting that a simple blood draw can reveal critical information about the biology of a tumor, from identifying mutations and guiding treatment to monitoring residual disease and potentially detecting cancer earlier.

We'll dive into the science behind liquid biopsy and circulating tumor DNA, Guardant's evolution from Guardant360 into a broader precision-oncology platform, the rise of its Shield colorectal cancer screening test, and the company's growing role in pharmaceutical drug development, real-world evidence, and AI. We'll also explore the promise and major challenges of multi-cancer early detection, including the questions around sensitivity, false positives, reimbursement, and whether detecting cancer earlier actually translates into better outcomes.

Because the future of cancer care may not just be about developing better treatments, but about being able to continuously read what cancer is doing inside the body from something as simple as a blood sample.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #GuardantHealth #LiquidBiopsy #Cancer #Oncology #Biotech #Healthcare #PrecisionMedicine #CancerDetection #Genomics #ctDNA #Diagnostics #HealthTech #Pharma #AI #Biotechnology #FutureOfHealthcare

Transcript

Copy Transcript Copied

Hello and welcome to Petri Dish Perspectives, the podcast where we geek out about science and the companies shaping the future of healthcare. I'm your host, Manead, and I'm a PhD scientist by training, storyteller by choice. With every new episode released on Thursday, my goal is to deliver digestible pieces of information on healthcare companies under 30 mins.

Today we're talking about a company that is trying to fundamentally change one of the most important things in medicine: how we find, understand, and monitor cancer. If you've heard the term "liquid biopsy," Guardant Health is one of the companies you need to know. The basic idea sounds almost unbelievable: instead of needing to surgically remove a piece of a tumor to understand its biology, what if you could draw blood and find fragments of tumor DNA circulating through the bloodstream? That information could potentially tell physicians whether a patient has cancer, what mutations are driving that cancer, whether a treatment is working, and eventually whether a cancer might be coming back — all from a blood sample.

Guardant Health was founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, two scientists with deep backgrounds in genomics and sequencing. Since then, the company has evolved from a liquid-biopsy startup into a broader precision-oncology platform spanning cancer screening, treatment selection, therapy monitoring, pharmaceutical partnerships, and real-world data. The company generated approximately $982 million in revenue in 2025 and has continued growing rapidly in 2026, driven by its oncology testing business, pharmaceutical partnerships, and increasingly its Shield colorectal cancer screening test. But the really interesting question isn't simply whether Guardant is growing. It's whether the company can turn blood into something much more powerful: a real-time window into cancer biology.

Quick disclaimer, I give full credit to the original articles cited in the references in the transcript!

Grab a coffee or tea, settle in, and let’s jump in!

The Founders and the Original Bet

To understand Guardant, we need to start with its founders. Helmy Eltoukhy and AmirAli Talasaz didn't come together as traditional entrepreneurs looking for a healthcare business opportunity. They came from the world of genomic technology. Eltoukhy trained in electrical engineering at Stanford and had previously founded Avantome, a company focused on semiconductor sequencing that was acquired by Illumina. Talasaz also had a background at Illumina and had previously founded Auriphex Biosciences, which focused on circulating tumor cells and genetic analysis for cancer management. So both founders had already experienced the genomic revolution from the inside.

That background is important because they understood that sequencing technology was becoming incredibly powerful, but there was still a major translational problem: how do you actually get genomic information out of the laboratory and into routine clinical decision-making? Cancer presented an enormous opportunity. The genome of a tumor can tell you what mutations are driving it, how aggressive it may be, which therapies might work, and how it is evolving. But traditionally, getting that information meant getting tumor tissue. And tissue biopsies have limitations — tumors can be difficult to access, there may not be enough tissue, and one biopsy represents one location at one point in time.

Eltoukhy and Talasaz believed blood could provide a fundamentally different approach. Tumors shed biological material into the bloodstream, including fragments of DNA. If you could capture and analyze those fragments with sufficient sensitivity, you could potentially monitor cancer without repeatedly cutting into the tumor itself. That was the fundamental bet behind Guardant.

And it was a particularly ambitious bet because the technology had to overcome a very difficult biological problem. In a blood sample, the vast majority of DNA comes from normal cells. Tumor-derived DNA can represent only a tiny fraction of the total circulating DNA, particularly when a cancer is small or at an early stage. So Guardant wasn't simply trying to sequence DNA. It was trying to find a very small molecular signal inside an enormous background of normal biological information — and then determine whether that signal actually meant something clinically important.

Key Milestones: From Startup to Public Company

Before we get into the science, it helps to understand just how quickly Guardant moved from a founding thesis to a major publicly traded company. The timeline tells the story better than almost anything else.

Guardant was incorporated in 2011 and formally founded in 2012. By 2014, Guardant360 had launched commercially — just two years after founding. That's an unusually fast path from scientific concept to clinical product. By 2018, Guardant360 had been used by more than 5,000 oncologists, over 40 biopharmaceutical companies, and all 27 National Comprehensive Cancer Network centers.

In October 2018, Guardant went public on the Nasdaq under the ticker symbol GH, pricing its IPO at $19.00 per share and raising $237.5 million in gross proceeds. On its first day of trading, October 4, 2018, the stock opened at $27.75 — a 46% jump from the IPO price on day one. That kind of opening-day performance reflected how hungry investors were for precision oncology plays at the time, particularly companies that had already demonstrated real clinical adoption rather than just preclinical promise.

The capital raised at IPO helped fund what came next: expanding Guardant360 into additional cancers and clinical applications, building out the pharmaceutical partnerships business, investing in the LUNAR research programs focused on recurrence detection and early cancer detection, and ultimately developing Shield. In 2024, Shield received FDA approval for average-risk colorectal cancer screening in adults aged 45 and older — twelve years after the company was founded. And by 2025, Guardant was approaching $1 billion in annual revenue.

That arc — from founding thesis in 2012 to nearly $1 billion in revenue in 2025 — is worth holding onto as context for everything that follows. This isn't a concept company. It's a company that has already built real clinical infrastructure and demonstrated real commercial traction.

How Liquid Biopsy Works — and Why It's So Difficult

So let's actually break down the science behind liquid biopsy. When cancer cells grow, die, and release material into the bloodstream, they can shed fragments of DNA known as circulating tumor DNA, or ctDNA. These fragments can contain the genetic alterations present in the tumor. Theoretically, if you can isolate those fragments and sequence them, you can learn about the cancer without physically sampling the tumor.

But "theoretically" is doing a lot of work there.

The technical challenge is enormous. Imagine trying to find a few needles in an enormous molecular haystack. You have DNA from normal cells, immune cells, and other tissues, and only a small fraction may actually come from the tumor. The smaller the tumor, the less ctDNA may be available. That means the test needs to be extraordinarily sensitive while also avoiding false signals that come from normal biological variation.

Guardant built its platform around this problem. The company developed sequencing and computational approaches designed to identify cancer-associated genomic alterations from blood. Its flagship Guardant360 platform became particularly important in advanced cancer, where physicians increasingly need to understand the molecular characteristics of an individual patient's tumor to determine which therapies might be appropriate.

And this is where the technology fits into the broader evolution of oncology. We used to think about cancer largely based on where it occurred anatomically: lung cancer, breast cancer, colon cancer, and so on. But precision oncology has increasingly shifted toward asking what is happening at the molecular level. Two patients with the same anatomical cancer can have completely different mutations and therefore potentially respond to completely different treatments.

So Guardant's opportunity wasn't simply to create a new diagnostic test. It was to become part of the infrastructure supporting this shift toward molecularly informed cancer treatment.

From Diagnosis to Monitoring: Building a Precision Oncology Platform

Guardant360 was really the beginning of the story. Once you can identify cancer-associated mutations from blood, the obvious question becomes: what else can you do with that information?

One major application is treatment selection. Pharmaceutical companies are developing increasingly targeted therapies designed to work in patients whose tumors have specific molecular characteristics. That creates demand for diagnostic tests that can identify those patients. This is where companion diagnostics become important. A company developing a targeted cancer therapy may need a diagnostic test that determines which patients are appropriate for the drug, and Guardant has increasingly become part of that ecosystem.

This creates a very interesting business relationship between diagnostics and pharmaceutical companies. The pharmaceutical company develops the therapy, while Guardant can provide the molecular testing infrastructure that helps identify appropriate patients. The company has established partnerships and companion diagnostic relationships across the pharmaceutical industry, turning its technology into part of the drug-development process rather than simply selling a test directly to physicians.

But Guardant also realized that understanding a patient's cancer at one point in time isn't enough. You want to know how that cancer changes over time. Is treatment working? Is there still microscopic disease? Is the cancer beginning to develop resistance?

That is where technologies such as Guardant Reveal and the broader concept of minimal residual disease, or MRD, become important. After a patient has undergone surgery or treatment, imaging may not be sensitive enough to identify microscopic residual disease. ctDNA potentially provides a molecular signal that can be tracked over time. If tumor DNA disappears, that may indicate a favorable response. If it remains detectable, that could indicate residual disease. If it starts increasing again, it could potentially signal recurrence before conventional imaging detects it.

And that moves Guardant into a much more interesting position. It's no longer simply asking, "Does this patient have cancer?" It's asking, "What is the molecular state of this patient's cancer right now?"

That distinction could ultimately be enormously valuable because cancer is not static. It evolves. Treatment applies selective pressure. Resistant clones can emerge. A biopsy gives you a snapshot, while longitudinal blood testing potentially gives you a movie.

Shield: Taking Liquid Biopsy to Healthy People

But perhaps the biggest transformation in Guardant's business came when the company decided to take liquid biopsy beyond patients who already had cancer and into the world of cancer screening.

That's where Shield comes in.

Shield is Guardant's blood-based colorectal cancer screening test, which received FDA approval in 2024 for average-risk adults aged 45 and older. And this is a fundamentally different market from advanced oncology. Instead of asking an oncologist to order a liquid biopsy for a patient who already has cancer, Guardant is asking millions of relatively healthy people to take a blood test as part of routine preventive care.

Why would anyone want that?

Because cancer screening has a massive adherence problem.

Colonoscopy is an incredibly powerful screening tool. It can detect colorectal cancer and precancerous lesions, and it can actually remove polyps during the procedure. But it requires preparation, time, an invasive procedure, and often sedation and transportation. Stool-based screening is less invasive, but some people still don't want to deal with collecting and returning a stool sample.

Guardant is betting that a blood draw is easier.

And that distinction is important because Shield isn't necessarily competing with colonoscopy on the basis of being a technically superior test. In fact, it has limitations. A positive Shield test requires follow-up colonoscopy, and the test is less sensitive than colonoscopy for certain precancerous lesions. A negative test also doesn't mean someone has zero risk of colorectal cancer.

So the more interesting question is not necessarily, "Is Shield better than colonoscopy?" It's: "Can Shield get people screened who otherwise wouldn't get screened at all?"

That is a public-health question.

Guardant has reported very high adherence among early Shield users, and the test's availability has continued expanding through partnerships including Quest Diagnostics. In 2026, the American Cancer Society also added blood testing to its colorectal cancer screening options. If blood-based screening can materially increase the number of people who actually participate in screening, it could potentially produce a population-level benefit even if the individual test isn't as comprehensive as colonoscopy.

And that is a really interesting example of how healthcare innovation doesn't always mean creating the most technologically sophisticated test. Sometimes it means creating a test that people are actually willing to use.

The Bigger Bet: Data, AI, and Multi-Cancer Detection

This brings us to what I think is perhaps the most interesting part of Guardant's long-term strategy. The company doesn't want to simply become the company that sells a blood test. It wants to build a cancer data platform.

Every test generates information. Every tumor has genomic characteristics. Every treatment generates an outcome. Every longitudinal blood sample potentially adds another data point about how cancer behaves over time.

And when you combine enough of those data points, you can start asking much bigger questions.

Which mutations predict response to a particular therapy? Which molecular patterns predict recurrence? How does cancer evolve under treatment? Which patients are most likely to benefit from a particular drug? Can resistance be detected earlier? Can pharmaceutical companies use these datasets to improve clinical trials?

That's where Guardant's Infinity platform and InfinityAI capabilities become important. The company is increasingly positioning itself at the intersection of genomics, real-world evidence, and artificial intelligence. Instead of simply returning a test result, the ambition is to use the enormous amount of information generated through testing to produce insights that can be useful to physicians and pharmaceutical companies.

And Guardant has also been expanding beyond DNA. Its acquisition of MetaSight Diagnostics brought metabolomic capabilities into the company, reflecting a broader movement toward multiomics. DNA is only one layer of biology. RNA, proteins, metabolites, epigenetic information, and clinical phenotype all provide different perspectives on what's happening inside a patient.

The ultimate ambition is even bigger: multi-cancer detection.

Imagine going into a doctor's office, getting one blood draw, and having that sample analyzed for molecular signals associated with multiple different cancers. That's the promise behind Guardant's Shield Multi-Cancer Detection work.

But this is also where the scientific challenge becomes much greater. Detecting a cancer-associated signal isn't the same as proving that screening improves survival. You need to show that you're finding cancers early enough, accurately enough, and with sufficiently low false-positive rates that the benefits outweigh the harms of additional testing.

That distinction — between detecting something and proving that acting on it improves outcomes — is going to be one of the most important questions in the entire liquid-biopsy industry.

The Competition and What Could Go Wrong

Guardant is operating in an increasingly competitive market. Grail has developed Galleri, a multi-cancer early-detection test. Exact Sciences has built a major diagnostics business around colorectal cancer screening and is also pursuing broader cancer detection technologies. There are also numerous companies working on liquid biopsy, circulating DNA, methylation, protein biomarkers, RNA, and other approaches to early cancer detection.

And ultimately, these companies aren't just competing on technology. They're competing over patient behavior, physician trust, reimbursement, regulatory approval, and clinical outcomes.

That's because the risks in this market are substantial.

The first is sensitivity. Early-stage cancers may release extremely small amounts of ctDNA, making them much harder to detect. The second is false positives. If a test incorrectly tells someone they might have cancer, that can lead to imaging, invasive procedures, anxiety, and potentially unnecessary treatment. The third is false negatives. A negative result can create false reassurance, particularly if people misunderstand what the test actually means. Then there's reimbursement. A diagnostic can be scientifically impressive but commercially unsuccessful if insurers aren't willing to pay for it. And finally, there's clinical utility. This may be the biggest hurdle of all. The industry needs to prove that using these tests actually changes outcomes.

It's not enough to say, "Our test detected cancer six months earlier." The question is: Did detecting it six months earlier make the patient live longer or live better?

That's a much harder scientific question. And I think it's one of the reasons Guardant is such a fascinating company to follow. The technology is compelling, but the ultimate validation has to happen in the healthcare system itself.

Lessons from Guardant

But I don't think Guardant's ultimate moat is simply its sequencing technology.

The more interesting moat is the combination of test volume, clinical data, pharmaceutical relationships, regulatory experience, reimbursement infrastructure, computational capabilities, and longitudinal patient information. Think about what happens every time another patient gets tested. You get another tumor profile. You potentially get another treatment outcome. You potentially get another longitudinal data point. You potentially get another piece of information that can improve understanding of how cancer behaves.

And that creates a data flywheel.

This is also where I see an interesting parallel to the Epic episode we did previously. Epic's power isn't just that it makes electronic health records. Its power comes from being deeply embedded in healthcare workflows and accumulating enormous amounts of clinical information. Guardant is trying to build something different, but potentially analogous in molecular medicine: an infrastructure layer that sits between the patient's blood, their cancer biology, their physician, and the pharmaceutical industry.

If that works, Guardant becomes much more than a diagnostics company. It becomes part of the infrastructure of precision oncology.

What’s Next for Guardant?

So where does Guardant go from here?

The company needs to continue scaling Shield while demonstrating that real-world adoption translates into meaningful improvements in colorectal cancer screening. It needs to expand Guardant360 and Reveal into additional cancers and clinical applications. It needs to continue building its relationships with pharmaceutical companies and prove that its data and AI capabilities can generate meaningful value for drug development.

And perhaps most importantly, it needs to determine whether multi-cancer detection can move from an exciting scientific concept into a clinically validated and economically viable screening paradigm.

Because if you step back and look at Guardant's entire strategy, there's actually a very coherent vision. First, detect cancer. Then characterize it. Then identify the appropriate therapy. Then monitor whether the therapy is working. Then look for minimal residual disease. Then detect recurrence. And eventually, potentially detect multiple cancers before symptoms appear.

In other words, Guardant is trying to make blood the interface between the patient and the biology of their cancer. And I think that's ultimately why this company is so interesting.

Outro

For decades, cancer diagnosis has depended heavily on imaging, pathology, and tissue biopsies. Guardant's vision is that blood could increasingly provide a molecular snapshot of what's happening inside the body without having to physically access the tumor.

Imagine a future where a blood draw can help identify whether you have a molecular signal associated with cancer, characterize that cancer, identify the mutations driving it, help your physician select a therapy, monitor whether the therapy is working, detect residual disease, and potentially identify recurrence before you develop symptoms.

That's the promise. But the responsibility is equally significant. Because the more powerful these tests become, the more important it becomes to prove that the information they provide actually improves patients' lives.

And that's the question I would leave you with today: Are we entering an era where blood becomes the most important diagnostic window into the human body?

Guardant Health is betting heavily that the answer is yes. And if they're right, the future of cancer care may look very different — not because we've invented another blockbuster drug, but because we've developed a way to continuously read the biology of cancer from something as simple as a blood sample.

This has been Petri Dish Perspectives. I'm Manead. Thanks for listening. See you next Thursday. Goodbye.

References

1. https://guardanthealth.com/ 
2. www.wikipedia.org
3. https://endpoints.news/ 
4. https://finance.yahoo.com/ 

© 2026 The Perspective Bureau LLC. All rights reserved.